Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Harvard Business School
Dow
Fuji
Baxter
Covington
Cipla
UBS
Citi
Moodys

Generated: October 17, 2017

DrugPatentWatch Database Preview

Maraviroc - Generic Drug Details

« Back to Dashboard

What are the generic sources for maraviroc and what is the scope of maraviroc patent protection?

Maraviroc
is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in two NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Maraviroc has two hundred and fifty-three patent family members in fifty-nine countries and fifteen supplementary protection certificates in eleven countries.

There are two drug master file entries for maraviroc. Four suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: maraviroc

US Patents:4
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: see list2
Suppliers / Packagers: see list4
Bulk Api Vendors: see list45
Clinical Trials: see list125
Patent Applications: see list3,089
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:maraviroc at DailyMed

Pharmacology for Ingredient: maraviroc

Tentative approvals for MARAVIROC

Applicant Application No. Strength Dosage Form
u► Subscribe150MGTABLET;ORAL
u► Subscribe300MGTABLET;ORAL
u► Subscribe300MGTABLET;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-001Aug 6, 2007RXYesNo► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-003Nov 4, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-002Aug 6, 2007RXYesYes► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-003Nov 4, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-002Aug 6, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-004Nov 4, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
SOLUTION;ORAL208984-001Nov 4, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-004Nov 4, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
SOLUTION;ORAL208984-001Nov 4, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Viiv Hlthcare
SELZENTRY
maraviroc
TABLET;ORAL022128-001Aug 6, 2007RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: maraviroc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,503,905 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives► Subscribe
7,041,667CCR5 modulators► Subscribe
7,217,714CCR5 modulators► Subscribe
6,586,431 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: maraviroc

Country Document Number Estimated Expiration
Norway2010007► Subscribe
Spain2311126► Subscribe
Czech Republic20012297► Subscribe
Spain2215129► Subscribe
Montenegro00555► Subscribe
Estonia05170► Subscribe
African Intellectual Property Organization (OAPI)11743► Subscribe
Eurasian Patent Organization200401056► Subscribe
Slovakia9012001► Subscribe
Turkey200101867► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: MARAVIROC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008 004, C 1284974Lithuania► SubscribePRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 20070918
2008004Lithuania► SubscribePRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010 20070918
417Luxembourg► Subscribe91417, EXPIRES: 20220918
C0007France► SubscribePRODUCT NAME: MARAVIROC; REGISTRATION NO/DATE: EU/1/07/418/001 20070918
C008/2008Ireland► SubscribeSPC008/2008: 20081105, EXPIRES: 20220917
00338Netherlands► SubscribePRODUCT NAME: MARAVIROC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
2008Austria► SubscribePRODUCT NAME: MARAVIROC, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918
2008 00018Denmark► Subscribe
C/GB08/014United Kingdom► SubscribePRODUCT NAME: MARAVIROC, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/07/418/001 20070918; UK EU/1/04/418/002 20070918; UK EU/1/04/418/003 20070918; UK EU/1/04/418/004 20070918; UK EU/1/04/418/005 20070918; UK EU/1/04/418/006 20070918; UK EU/1/04/418/007 20070918; UK EU/1/04/418/008 20070918; UK EU/1/04/418/009 20070918; UK EU/1/04/418/010 20070918
4Finland► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Federal Trade Commission
AstraZeneca
Queensland Health
Express Scripts
Medtronic
McKinsey
UBS
Fuji
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot